Mutant sodium channel for tumor therapy

Bakhos A. Tannous*, Adam P. Christensen, Lisa Pike, Thomas Wurdinger, Katherine F. Perry, Okay Saydam, Andreas H. Jacobs, Jaime García-Añoveros, Ralph Weissleder, Miguel Sena-Esteves, David P. Corey, Xandra O. Breakefield

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Viral vectors have been used to deliver a wide range of therapeutic genes to tumors. In this study, a novel tumor therapy was achieved by the delivery of a mammalian brain sodium channel, ASIC2a, carrying a mutation that renders it constitutively open. This channel was delivered to tumor cells using a herpes simplex virus-1/Epstein-Barr virus (HSV/ EBV) hybrid amplicon vector in which gene expression was controlled by a tetracycline regulatory system (tet-on) with silencer elements. Upon infection and doxycycline induction of mutant channel expression in tumor cells, the open channel led to amiloride-sensitive sodium influx as assessed by patch clamp recording and sodium imaging in culture. Within hours, tumor cells swelled and died. In addition to cells expressing the mutant channel, adjacent, noninfected cells connected by gap junctions also died. Intratumoral injection of HSV/EBV amplicon vector encoding the mutant sodium channel and systemic administration of doxycycline led to regression of subcutaneous tumors in nude mice as assessed by in vivo bioluminescence imaging. The advantage of this direct mode of tumor therapy is that all types of tumor cells become susceptible and death is rapid with no time for the tumor cells to become resistant.

Original languageEnglish (US)
Pages (from-to)810-819
Number of pages10
JournalMolecular Therapy
Issue number5
StatePublished - 2009

ASJC Scopus subject areas

  • Drug Discovery
  • Genetics
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology


Dive into the research topics of 'Mutant sodium channel for tumor therapy'. Together they form a unique fingerprint.

Cite this